Monotherapy achieved a CR rate of 83% (5 of 6 patients) in a pediatric ALK-positive ALCL groupMonotherapy achieved an ORR of 90.9% in a heavily pretreated, ALK-positive ALCL groupMonotherapy achieved an ORR of 83.3% with a CR rate of 58.3% in a R/R ALK-positive ALCL group. Here, ALK is linked to anaplastic large cell lymphoma.